Ajanta Pharma Limited (BOM: 532331)
India
· Delayed Price · Currency is INR
2,851.70
-26.90 (-0.93%)
At close: Dec 20, 2024
Ajanta Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
Net Income | 8,750 | 8,162 | 5,880 | 7,127 | 6,539 | 4,677 | Upgrade
|
Depreciation & Amortization | 1,319 | 1,304 | 1,267 | 1,214 | 1,114 | 924.8 | Upgrade
|
Other Amortization | 50.1 | 50.1 | 41 | 39.4 | 46.9 | 32.4 | Upgrade
|
Loss (Gain) From Sale of Assets | 6.6 | -34.9 | 61.9 | 38.7 | 22.1 | 1 | Upgrade
|
Loss (Gain) From Sale of Investments | 211.4 | 91.1 | 14.8 | -52.3 | 51.9 | 18.8 | Upgrade
|
Stock-Based Compensation | 63.7 | 54.9 | 2.2 | 3 | 0.2 | 4.2 | Upgrade
|
Other Operating Activities | -681.2 | -778.4 | -14.1 | -748.2 | 76.8 | 141.1 | Upgrade
|
Change in Accounts Receivable | 1,246 | -1,789 | -105.5 | -2,697 | 311.3 | -2,684 | Upgrade
|
Change in Inventory | -598.4 | -123 | -223.7 | -256.6 | -2,715 | -589.3 | Upgrade
|
Change in Accounts Payable | 599.1 | 408.5 | 969.1 | -480.2 | 111.5 | 1,328 | Upgrade
|
Change in Other Net Operating Assets | 659.2 | 505.6 | 28.6 | 1,430 | 204.2 | 713.4 | Upgrade
|
Operating Cash Flow | 11,625 | 7,851 | 7,921 | 5,617 | 5,763 | 4,568 | Upgrade
|
Operating Cash Flow Growth | 41.79% | -0.89% | 41.02% | -2.53% | 26.17% | 21.96% | Upgrade
|
Capital Expenditures | -2,498 | -1,524 | -1,745 | -1,488 | -1,716 | -2,394 | Upgrade
|
Sale of Property, Plant & Equipment | 133.7 | 133.8 | 7.3 | 183.8 | 17.1 | 54.9 | Upgrade
|
Investment in Securities | -4,676 | 1,776 | -3,907 | 287.8 | -1,255 | -16.8 | Upgrade
|
Other Investing Activities | 478.5 | 267.9 | 48.7 | 275.8 | 129.7 | 112 | Upgrade
|
Investing Cash Flow | -6,562 | 653.9 | -5,596 | -741 | -2,824 | -2,244 | Upgrade
|
Long-Term Debt Issued | - | 0.6 | - | 2.3 | - | 97.3 | Upgrade
|
Total Debt Issued | 9.9 | 0.6 | - | 2.3 | - | 97.3 | Upgrade
|
Long-Term Debt Repaid | - | -125.5 | -112.3 | -137.5 | -626 | -152.7 | Upgrade
|
Total Debt Repaid | -123.8 | -125.5 | -112.3 | -137.5 | -626 | -152.7 | Upgrade
|
Net Debt Issued (Repaid) | -113.9 | -124.9 | -112.3 | -135.2 | -626 | -55.4 | Upgrade
|
Repurchase of Common Stock | -3,527 | -3,883 | - | -2,856 | -1,354 | - | Upgrade
|
Common Dividends Paid | -3,274 | -6,422 | -896.9 | -822.1 | -829 | -1,134 | Upgrade
|
Other Financing Activities | -118.2 | -81.3 | -72.8 | -783.9 | -373.8 | -96.5 | Upgrade
|
Financing Cash Flow | -7,033 | -10,511 | -1,082 | -4,597 | -3,183 | -1,286 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | - | - | - | - | 0.1 | Upgrade
|
Net Cash Flow | -1,970 | -2,006 | 1,243 | 279 | -243.6 | 1,037 | Upgrade
|
Free Cash Flow | 9,127 | 6,327 | 6,176 | 4,129 | 4,047 | 2,174 | Upgrade
|
Free Cash Flow Growth | 38.08% | 2.44% | 49.59% | 2.02% | 86.20% | 589.12% | Upgrade
|
Free Cash Flow Margin | 20.32% | 15.03% | 16.50% | 12.36% | 14.00% | 8.40% | Upgrade
|
Free Cash Flow Per Share | 72.60 | 50.21 | 48.21 | 31.84 | 30.98 | 16.60 | Upgrade
|
Cash Interest Paid | 107.3 | 72.1 | 58.4 | 102 | 49.6 | 71.6 | Upgrade
|
Cash Income Tax Paid | 3,355 | 3,121 | 1,513 | 2,391 | 2,304 | 1,573 | Upgrade
|
Levered Free Cash Flow | 7,362 | 1,165 | 8,146 | 1,893 | 3,096 | 804.95 | Upgrade
|
Unlevered Free Cash Flow | 7,430 | 1,210 | 8,183 | 1,956 | 3,148 | 879.39 | Upgrade
|
Change in Net Working Capital | -1,433 | 5,211 | -4,369 | 2,860 | 1,868 | 1,361 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.